No matter which nucleic acids you develop as therapeutics, biomarkers or similar, we offer you the quantification of your nucleic acids and oligonucleotides in various biological matrices. We develop standardized and reproducible methods under GLP according to the latest guidelines for many substance groups
Groups of substances
- RNA Therapeutics: AntagomiRs
- small non-coding RNAs:
- miRNAs (precursors and mature)
We support you in many areas of your research. Benefit from our experience in active substance and biomarker development.
- Active substance or biomarker search/development
- Preclinical studies:
- Dose-finding studies
- Toxicological studies
- Pharmacokinetic studies
- Toxicokinetic studies
- Clinical trials (Phases 0-III)
- Bioequivalence/bioavailability studies
For several years we have been conducting intensive research in the field of miRNA analytics. In our project funded by ZIM we have succeeded in establishing a GLP validated method for the determination of miRNAs in plasma. In another project we are developing a diagnostic test based on the miR-574-5p as a predictive biomarker for the identification of patients with PGE2-mediated tumor growth (here bronchial carcinoma and colorectal carcinoma) who may benefit from the application of NSARs and/or mPGES-1 inhibitors.
Our research results have been published now in the FASEB BIO Advances Journal.